FK228, also known as Romidepsin or FK-228, is a small molecule inhibitor of histone deacetylase (HDAC). It was first isolated from the bacterium Chromobacterium violaceum in 1994 and has since been studied for its potential as a cancer treatment.
Chemical name:
The chemical name for FK228 is (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentanone.
Molecular formula:
The molecular formula of FK228 is C24H36N4O6S2.
Formula weight:
The formula weight of FK228 is 540.69 g/mol.
CAS No:
The CAS number of FK228 is 128517-07-7.
Top ten keywords from Google and Synonyms:
Synonyms:
Health benefits of this product:
FK228 has been primarily developed for the treatment of cancer. It is a selective inhibitor of HDAC, which plays an important role in gene expression and is often dysregulated in cancer cells. By inhibiting HDAC, FK228 may help to restore normal gene expression and slow or stop the growth of cancer cells.
Potential effects:
Some potential effects of FK228 include:
Product mechanism:
FK228 works by inhibiting HDAC, which is an enzyme that regulates gene expression. HDAC is often overexpressed or mutated in cancer cells, leading to their uncontrolled growth and survival. By inhibiting HDAC, FK228 may help to restore normal cellular signaling and slow or stop the growth of cancer cells.
Safety:
FK228 has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with FK228.
Side effects:
FK228 can cause several side effects in some patients. These can include:
Dosing information:
The optimal dosing regimen of FK228 has not yet been established and further research is needed to determine the most effective dose. Doses ranged from 0.25 mg/m2 to 24 mg/m2 per day in preclinical studies. In clinical trials, doses ranged from 8 mg/m2 to 18 mg/m2 per day. The drug is typically administered intravenously.
Conclusion:
FK228, also known as Romidepsin, is a small molecule inhibitor of HDAC that has shown potential as a treatment for cancer. By inhibiting HDAC, FK228 may help to restore normal gene expression and slow or stop the growth of cancer cells. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of FK228 in treating cancer.
